Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Aliskiren is a direct renin inhibitor used to manage hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.
- Mechanism
- Curator reviewed · 3 references
Aliskiren is a renin inhibitor. Renin is secreted by the kidneys when blood volume and renal perfusion decrease. It normally cleaves the protein angiotensinogen to form angiotensin I. Angiotensin I is then converted to angiotensin II, an active protein. Angiotensin II is a potent vasoconstrictor that causes the release of catecholamines into the circulation. It also promotes the secretion of aldosterone in addition to sodium reabsorption, increasing blood pressure. Additionally, angiotensin II acts on the adrenal cortex where it stimulates aldosterone release. Aldosterone increases sodium reabsorption and potassium excretion in the nephron.
Aliskiren prevents the above process via binding to renin at its active site, stopping the cleavage of angiotensin, in turn inhibiting the formation of angiotensin I. This ends the cascade of angiotensin II mediated mechanisms that normally increase blood pressure.
- Primary indication
- Aliskiren is used for the treatment of hypertension in children above 6 years and adults.Curator reviewed · 3 structured indications
- Formula / weight
- C30H53N3O6 · 551.7583 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2007 · European Union, 2016
- Code names
- CGP 60536 · CGP60536B · SPP 100
- Brand names
- Rasilez
- Tekturna
- Tekturna Hct
Resolves to
UXOWGYHJODZGMF-QORCZRPOSA-NSMILESCOCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1What you can answer from here — as of September 14, 2026
Which drugs share a target with Aliskiren, and which of those have an active Phase 3 trial?